|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...9596979899100101102103104105...39323933» |
- Bavencio (avelumab) / EMD Serono, Stivarga (regorafenib) / Bayer
Regomune study : A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC) (Pamplona Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1760;
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG) (Pamplona Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1742;
- PF-08046054 / Pfizer
Interim Results of a Phase 1 Study of SGN-PDL1V (PF-08046054) in Patients with PDL1-Expressing Solid Tumors (Santander Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1739;
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab for HPV-associated Recurrent Respiratory Papillomatosis (Burgos Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1732;
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, BND-22 / Biond Biologics, Sanofi
Final results from Phase 1, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors (Burgos Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1730;
- Tecentriq (atezolizumab) / Roche
A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma (Burgos Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1727;
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib (Santander Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1711;
P2
Conclusions The LENVAGIST study met its primary endpoint. Lenvatinib leads to clinical benefits in pts presenting advanced GIST after failure of available TKIs.
- Keytruda (pembrolizumab) / Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca
Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD), (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1707;
- retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA) (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1699;
P3
Grade ?3 TRAEs were comparable between the two arms (62.6% vs 59.0%), with the most common being decreased platelet count (19.0% vs 28.1%), decreased neutrophil count (12.1% vs 16.4%), and anemia (19.8% vs 12.6%). Conclusions 1L SHR-1701 plus CAPOX showed a statistically significant and clinically meaningful benefit in OS compared with placebo plus CAPOX in pts with HER2-negative G/GEJA, both in PD-L1 CPS ?5 population and in overall population regardless of PD-L1 level, presenting as a new treatment option.
- Opdivo (nivolumab) / BMS
Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer: A phase 2 POTENTIAL study. (Sevilla Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1692;
- Opdivo (nivolumab) / BMS
Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma (Sevilla Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1684;
- Opdivo (nivolumab) / BMS
Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: a phase II, randomized study by the Hellenic GU Cancer Group. (Sevilla Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1683;
- GemRIS (gemcitabine-releasing intravesical system) / J&J, cetrelimab (JNJ-63723283) / J&J
TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4) (Sevilla Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1679;
P2
T1 at RC and ?1/2 pts achieved pCR. SR-4 interim results support further investigation of TAR-200 + CET in pts with MIBC.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecularly selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (Madrid Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1663;
P2
Durable benefit was seen across MMRd, hTMB, BRCA2m and CDK12i subgroups. Outcomes to dual ICB in pts with MMRd appear superior than what was previously reported for ICB monotherapy.
- relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs) (Barcelona Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1653;
P2
Most common adverse events included endocrinopathies: hypothyroidism (40.0% in nivo/ipi, 33.3% in nivo/rela), adrenal insufficiency (26.7% in nivo/ipi, 6.7% in nivo/rela) and diabetes (6.7% in nivo/rela). Conclusions We present the first exploratory clinical trial with short-term neoadjuvant immunotherapy without chemotherapy for patients with TNBC with high TILs and observed a pCR rate of 33% with nivo/ipi and 47% with nivo/rela, warranting further studies on efficacy and toxicity of chemotherapy-free immunotherapy for immunogenic TNBC.
- oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC) (Barcelona Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1652;
P2
Final statistical analysis will be presented at the conference. Ongoing translational research will shed light on the mechanisms of response.
- Kisqali (ribociclib) / Novartis
Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer (Barcelona Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1650;
- tibremciclib (BPI-16350) / Betta Pharma
Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study (Barcelona Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1649;
- BNT327 / BioNTech
A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002/BNT327 in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer (Barcelona Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1646;
- Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC) (Barcelona Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1645;
- Verzenio (abemaciclib) / Eli Lilly
ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria (Barcelona Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1644;
P2
Safety analysis is ongoing and will be presented at the meeting. Conclusions ABIGAIL confirms that first-line abemaciclib + ET achieves a higher early ORR compared to paclitaxel in HR+/HER2- ABC pts with aggressive disease criteria.
- Keytruda (pembrolizumab) / Merck (MSD)
KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) and investigational agents followed by adjuvant pembro for stage IIIB-D melanoma (Salamanca Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1642;
- WNT974 / Novartis, spartalizumab (PDR001) / Novartis
Phase 1 study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma (Oviedo Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1641;
- Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
Sitravatinib Plus Tislelizumab for Metastatic Uveal Melanoma with Liver Metastasis: The Open-Label, Multicenter, Phase II GEM-2101 Trial (Oviedo Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1640;
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-Up, rechallenge, and crossover in KEYNOTE-716 (Oviedo Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1637;
- Opdivo (nivolumab) / BMS
Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K (Oviedo Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1636;
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial (Oviedo Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1634;
P2
Conclusions ABIGAIL confirms that first-line abemaciclib + ET achieves a higher early ORR compared to paclitaxel in HR+/HER2- ABC pts with aggressive disease criteria. Methods The 1:1 randomised phase 2 ImmunoCobiVem trial compared
- Opdivo (nivolumab) / BMS, vusolimogene oderparepvec (RP1) / Replimune
Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti (Oviedo Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1633;
P2
Methods The 1:1 randomised phase 2 ImmunoCobiVem trial compared Conclusions RP1 + nivo provided durable, clinically meaningful, antitumor activity with mostly grade 1
- Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / BMS
Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study (Oviedo Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1632;
P3
Antitumor activity was also observed in some pts who received second-course pembro. These results confirm that pembro provides long-term benefit for advanced melanoma, supporting it as a standard of care in this setting.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma (Oviedo Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1631;
P3
Conclusions Final results from CheckMate 067 continue to demonstrate a sustained, long-term survival benefit across subgroups in the NIVO-containing arms, underscoring how checkpoint inhibitors have transformed the long-term prognosis for pts with advanced melanoma. There is now a potential for cure in pts responsive to these treatments.
- Cabometyx (cabozantinib tablet) / Exelixis, Tecentriq (atezolizumab) / Roche
Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study (Valencia Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1627;
P3
Methods Pts with mCRPC whose disease progressed on one prior NHT and who had measurable extrapelvic nodal or visceral disease were randomized 1:1 to C+A or NHT (abiraterone + prednisone or enzalutamide)...Baseline characteristics were balanced between treatment arms: 79%/76% had bone metastasis (BM), 23%/23% had liver metastases (LM), and 22%/22% had received prior docetaxel...Final OS, the 2nd dual primary endpoint, favored C + A (HR 0.89), but did not achieve statistical significance. A survival advantage was seen in some subgroups (e.g. liver metastasis, bone metastasis) The tolerability profile of C+A was similar to other approved TKI/ICI combinations in pts with advanced cancers.
- Keytruda (pembrolizumab) / Merck (MSD), ImmuFact (eftilagimod alpha) / Immutep
Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ?1 (Valencia Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1619;
P2
E+P resulted in numerically higher ORR & DCR compared to P only in CPS ?1 pts, with the largest differential in CPS ?20. Conclusions E+P is well tolerated with positive efficacy data and should be investigated further in HNSCC.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Nivolumab and Ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial (Burgos Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1610;
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Final overall survival (OS) from the Phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR) (Burgos Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1609;
- Bavencio (avelumab) / EMD Serono
Avelumab + methotrexate to eradicate low-risk gestational trophoblastic tumors in 1st-line setting: TROPHAMET phase I/II trial. (Sevilla Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1607;
- Keytruda (pembrolizumab) / Merck (MSD), gotistobart (BNT316) / OncoC4, BioNTech
A randomized, phase II, dose optimization of gotistobart, a pH-sensitive anti-CTLA-4, in combination with standard dose pembrolizumab in platinum-resistant recurrent ovarian cancer: Safety, efficacy and dose optimization (PRESERVE-004/GOG-3081) (Burgos Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1602;
P2
Unconfirmed ORR was 31.8% (7/22; 95% CI 13.9-54.9) and 36.4% (8/22; 95% CI 17.2-59.3) in 1 mg/kg and 2 mg/kg groups, respectively. Conclusions Early results show encouraging safety and clinical activity in PROC patients receiving gotistobart + pembrolizumab.
- Avastin (bevacizumab) / Roche, Kaitanni (cadonilimab) / Akesobio
Cadonilimab plus Chemotherapy (Burgos Auditorium - Hall 5) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1601;
- Keytruda (pembrolizumab) / Merck (MSD), Aidixi (disitamab vedotin) / Pfizer
Preliminary Efficacy And Safety Of Disitamab Vedotin (DV) With Pembrolizumab (P) In Treatment (Tx)-Naive HER2-Expressing, Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): RC48G001 Cohort C (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1599;
- Keytruda (pembrolizumab) / Merck (MSD), Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
EV-302: Exploratory Analysis of Nectin-4 Expression and Response to 1L Enfortumab Vedotin (EV) + Pembrolizumab (P) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (la/mUC) (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1598;
- Keytruda (pembrolizumab) / Merck (MSD), Lytgobi (futibatinib) / Otsuka
Phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1597;
- Keytruda (pembrolizumab) / Merck (MSD)
Alliance A031501: AMBASSADOR Study of Adjuvant Pembrolizumab (Pembro) in Muscle-Invasive Urothelial Carcinoma (MIUC) vs Observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1595;
- Inlyta (axitinib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1591;
P1/2
Safety: only 1 pt in the pbo arm reported FMT/pbo-related adverse event (grade 3 oral mucositis) and discontinued capsules assumption. Conclusions The preliminary results of TACITO trial show for the first time the role of FMT in increasing the activity of ICIs-based therapies in mRCC pts.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100) (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1590;
P3
Conclusions Benmelstobart plus Anlotinib provided superior PFS and ORR compared with sunitinib, and had manageable safety in pts with previously untreated advanced RCC. These results support the use of Benmelstobart plus anlotinib as a new first-line treatment for advanced RCC.
- GemRIS (gemcitabine-releasing intravesical system) / J&J, cetrelimab (JNJ-63723283) / J&J
TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Gu (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1589;
P2
CET alone provided modest CR rate comparable to other anti-PD-(L)1 agents. Results from C1, C2, and C3 support the continued development of TAR-200 monotherapy in pts with BCG UR HR NMIBC.
- Keytruda (pembrolizumab) / Merck (MSD)
IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort (Sevilla Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1587;
- relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study. (Sevilla Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1586;
- Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial (Madrid Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1584;
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2 (Sevilla Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1582;
P2
Conclusions Here we show a 100% 3-year DFS in patients with dMMR colon cancer treated with one dose of ipilimumab and two doses of nivolumab prior to surgery. The survival data are also supported by negative ctDNA at the MRD timepoint in all patients, while on-treatment ctDNA dynamics provide an additional monitoring instrument for future trials on organ preservation.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1570;
P2
Conclusions Lenvatinib combined with pembrolizumab is a potential standard treatment in pre-treated advanced B3-thymoma and thymic carcinoma. Toxicity profile is manageable but close monitoring is advised.
- Imfinzi (durvalumab) / AstraZeneca
Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial (Bilbao Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1569;
P3
Toxicity profile is manageable but close monitoring is advised. Methods cCRT comprised either once-daily (QD) or twice-daily (BID) thoracic radiotherapy (RT) and 3/4 cycles of platinum-etoposide chemotherapy (CT),